A record number of new oncology drugs has been approved in recent years, bringing new treatment options to patients.
We are seeing more targeted therapies, even for niche indications, with several therapeutic options to address the same molecular targets. The types of treatments being developed range from chemotherapy, small molecules and oral drug formulations all the way to cancer vaccines, immune cell therapies, cytokine modulation and monoclonal antibodies.
Despite robust levels of pipeline activity, oncology remains one of the most challenging areas for research and development where the competition is high, the risk of failure is significant, and the timeline from bench to bedside is long.
In the development phase, there are critical junctures where the right environment is crucial for success.
This is where partnering can increase the chances for the best science to come to fruition. For many early-stage biotech companies, this means avoiding the ‘valley of death’. For biopharmaceutical companies, this means finding the treatments that improve patient lives.
Oncology Virtual Partnering Event: Where the best science comes to meet
Inova’s aim is to accelerate partnering by facilitating the bridge between science and business. From 22 to 24 September, Inova in collaboration with BIO, are organizing a 3-day virtual partnering event on oncology, where researchers, biotech companies and business development executives from biopharmaceutical companies will be able to network in a virtual space.
Through one-on-one meetings, they will discuss the latest research from oncology congresses, pitch ideas and partner to prioritize research efforts that hold the most promise.
Cancer is not just one disease but many, each with its own characteristics, risk factors, causes and treatments. This complexity calls for an incredible effort to decipher the disease and to drive innovation in oncology. We believe this is a unique opportunity for the scientific and business community to connect, for the benefit of patients worldwide.